Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Capper

Showing results (311-320 of 350) with videos related to

Pageof 35
Sort By:
Acta Neuropathologica|May 7, 2018
DNA methylation-based reclassification of olfactory neuroblastomaDavid Capper, Nils W Engel, Damian Stichel, et al.
Neuro-Oncology|November 6, 2024
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective studyAlexander P Landry, Justin Z Wang, Vikas Patil, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Neuro-Oncology|June 3, 2026
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all AgesAbigail K Suwala, Dennis Friedel, Felix E Hinz, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Acta Neuropathologica|November 26, 2025
Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomasFelix E Hinz, Dennis Friedel, Franziska M Ippen, et al.
The Lancet. Oncology|September 4, 2025
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysisKarenna J Groff, Ruchit V Patel, Yang Feng, et al.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Biorxiv : the Preprint Server for Biology|August 23, 2023
Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerabilityRichard Drexler, Robin Khatri, Thomas Sauvigny, et al.
Acta Neuropathologica|April 25, 2018
Novel, improved grading system(s) for IDH-mutant astrocytic gliomasMitsuaki Shirahata, Takahiro Ono, Damian Stichel, et al.
Pageof 35

Showing results (311-320 of 350) with videos related to

Sort By:
Pageof 35
Acta Neuropathologica|May 7, 2018
DNA methylation-based reclassification of olfactory neuroblastomaDavid Capper, Nils W Engel, Damian Stichel, et al.
Neuro-Oncology|November 6, 2024
Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: A multicenter prospective studyAlexander P Landry, Justin Z Wang, Vikas Patil, et al.
Neuro-Oncology|May 19, 2026
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade GliomaChelsea Kotch, Sebastien Perreault, Phoebe Power, et al.
Neuro-Oncology|June 3, 2026
Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all AgesAbigail K Suwala, Dennis Friedel, Felix E Hinz, et al.
Acta Neuropathologica Communications|October 30, 2019
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entitiesAnnekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, et al.
Acta Neuropathologica|November 26, 2025
Loss of global DNA hypermethylation is prognostic in IDH-mutant and 1p/19q-codeleted oligodendrogliomasFelix E Hinz, Dennis Friedel, Franziska M Ippen, et al.
The Lancet. Oncology|September 4, 2025
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysisKarenna J Groff, Ruchit V Patel, Yang Feng, et al.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Biorxiv : the Preprint Server for Biology|August 23, 2023
Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerabilityRichard Drexler, Robin Khatri, Thomas Sauvigny, et al.
Acta Neuropathologica|April 25, 2018
Novel, improved grading system(s) for IDH-mutant astrocytic gliomasMitsuaki Shirahata, Takahiro Ono, Damian Stichel, et al.
Pageof 35